Etana-Celltrion tanda tangani MOU distribusikan dua obat terapi

Srutub.com Mudah mudahan kalian sehat dan berbahagia selalu. Disini aku ingin berbagi insight tentang Kesehatan, Farmasi, Bisnis yang menarik. Artikel Ini Menyajikan Kesehatan, Farmasi, Bisnis EtanaCelltrion tanda tangani MOU distribusikan dua obat terapi Pelajari detailnya dengan membaca hingga akhir.

Etana Biotechnologies and Celltrion Partner to Distribute Cancer Treatment Drugs in IndonesiaEtana Biotechnologies Indonesia (Etana), a local biopharmaceutical company, has partnered with global biopharmaceutical company Celltrion to distribute and market two innovative cancer treatment drugs in Indonesia. This partnership, marked by the signing of a Memorandum of Understanding (MOU), promises new hope for cancer patients in Indonesia by providing wider access to high-quality treatment.Etana's CEO, Nathan Tirtana, expressed the company's commitment to improving public health in Indonesia. "We are committed to providing high-quality, affordable, and innovative products to support the government's efforts in improving health in Indonesia," he said. The two cancer treatment drugs to be distributed are first-line therapies for breast cancer and non-Hodgkin's lymphoma and are listed in the National Formulary (Fornas) and e-catalog, ensuring accessibility and affordability for patients. This step is a significant milestone in the fight against cancer in Indonesia.Herzuma® and Truxima®: Innovative Targeted TherapiesThe two drugs that are the focus of this collaboration are Herzuma® (trastuzumab) and Truxima® (rituximab). Herzuma® is a targeted therapy for breast and gastric cancers. It works effectively on cancers that overexpress a particular protein known as human epidermal growth factor receptor 2 (HER2). Truxima® (rituximab) is an anti-CD20 targeted therapy used to treat chronic lymphocytic leukemia, follicular lymphoma, and non-Hodgkin's lymphoma. Truxima® can also be used to treat rheumatoid arthritis when other therapies are ineffective.The safety and efficacy of Herzuma® and Truxima® have been internationally recognized. Both drugs have received approval from the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Furthermore, Herzuma® and Truxima® have been marketed in more than 110 countries worldwide, demonstrating global trust and acceptance of these two innovative drugs.Positive Impact of the Etana and Celltrion PartnershipCelltrion's Southeast Asia Regional General Manager, Ji Tae Kim, expressed optimism about the collaboration. "We are very pleased to partner with Etana to bring trastuzumab and rituximab biosimilars to the Indonesian market," he said. Kim also stressed that this strategic partnership combines the strengths and expertise of both companies. The collaboration between Etana and Celltrion is not just about drug distribution, but also about a shared commitment to improving the quality of life for cancer patients in Indonesia. The availability of these innovative drugs is expected to provide new hope and opportunities for patients undergoing treatment.New Hope for Cancer Patients in IndonesiaThe agreement between Etana Biotechnologies and Celltrion marks a significant step forward in the fight against cancer in Indonesia. By providing access to high-quality, affordable treatment, this partnership offers new hope for patients and their families. The distribution of Herzuma® and Truxima® is expected to transform the cancer treatment landscape in Indonesia. This collaboration is not just a business partnership but also a commitment to improving public health and providing hope for those battling cancer. The availability of these drugs in Indonesia is a boon for patients who previously had difficulty accessing effective treatment. With more affordable prices, patients can receive better care without having to bear excessive financial burdens. This will also help improve the cure rate and quality of life for cancer patients in Indonesia. This partnership is clear evidence that innovation and collaboration can bring positive change to society.In addition, this collaboration will also have a positive impact on the development of the biopharmaceutical industry in Indonesia. With the transfer of knowledge and technology from Celltrion, local biopharmaceutical companies such as Etana can increase their capabilities in developing and producing innovative drugs. This will strengthen the health ecosystem in Indonesia and open up opportunities for the development of other drugs in the future.

Begitulah uraian mendalam mengenai etanacelltrion tanda tangani mou distribusikan dua obat terapi dalam kesehatan, farmasi, bisnis yang saya bagikan Terima kasih telah membaca hingga bagian akhir kembangkan potensi diri dan jaga kesehatan mental. sebarkan ke teman-temanmu. Sampai jumpa lagi